Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland.
Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland.
Int J Mol Sci. 2024 May 10;25(10):5212. doi: 10.3390/ijms25105212.
Atherosclerotic cardiovascular disease (ASCVD) stands as the leading cause of mortality worldwide. At its core lies a progressive process of atherosclerosis, influenced by multiple factors. Among them, lifestyle-related factors are highlighted, with inadequate diet being one of the foremost, alongside factors such as cigarette smoking, low physical activity, and sleep deprivation. Another substantial group of risk factors comprises comorbidities. Amongst others, conditions such as hypertension, diabetes mellitus (DM), chronic kidney disease (CKD), or familial hypercholesterolemia (FH) are included here. Extremely significant in the context of halting progression is counteracting the mentioned risk factors, including through treatment of the underlying disease. What is more, in recent years, there has been increasing attention paid to perceiving atherosclerosis as an inflammation-related disease. Consequently, efforts are directed towards exploring new anti-inflammatory medications to limit ASCVD progression. Simultaneously, research is underway to identify biomarkers capable of providing insights into the ongoing process of atherosclerotic plaque formation. The aim of this study is to provide a broader perspective on ASCVD, particularly focusing on its characteristics, traditional and novel treatment methods, and biomarkers that can facilitate its early detection.
动脉粥样硬化性心血管疾病(ASCVD)是全球范围内主要的致死原因。其核心是动脉粥样硬化的一个渐进过程,受多种因素影响。其中,生活方式相关因素较为突出,饮食不当是首要因素之一,此外还包括吸烟、低身体活动和睡眠不足等因素。另一个重要的危险因素是合并症。其中包括高血压、糖尿病(DM)、慢性肾脏病(CKD)或家族性高胆固醇血症(FH)等疾病。在阻止疾病进展方面,对抗上述危险因素极为重要,包括治疗潜在疾病。此外,近年来,人们越来越关注将动脉粥样硬化视为一种与炎症相关的疾病。因此,人们正在努力探索新的抗炎药物来限制 ASCVD 的进展。同时,研究也在进行中,旨在寻找能够洞察动脉粥样硬化斑块形成过程的生物标志物。本研究旨在提供 ASCVD 的更广泛视角,特别关注其特征、传统和新型治疗方法以及有助于早期检测的生物标志物。